<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276066</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201400795-N</org_study_id>
    <secondary_id>P50GM111152-01</secondary_id>
    <nct_id>NCT02276066</nct_id>
  </id_info>
  <brief_title>Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS</brief_title>
  <official_title>Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care Subtitle. Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the mechanism by which kidney dysfunction perpetuates inflammation,
      immunosuppression, and catabolism (PICS) in chronic critical illness. The investigators will
      test the hypothesis that persistent kidney dysfunction in sepsis associated by chronic
      critical illness contributes to decreased survival through the development of PICS. In
      chronic critical illness, the persistence of the inflammatory state may lead to capillary
      rarefication in the kidney causing accelerated chronic kidney disease. Progression of chronic
      kidney disease during chronic critical illness can drive PICS. Indeed, many of the features
      of chronic critical illness are consistent with the protein-energy malnutrition and muscle
      wasting associated with chronic kidney disease. Thus, the kidney can play a contributory role
      in chronic critical illness and PICS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal of this project is to measure kidney filtration function at day 14 or the day
      of discharge from hospital (whichever occurs first), in order to determine the presence and
      magnitude of persistent kidney dysfunction after sepsis episode and to longitudinally assess
      further decline of kidney function at one year follow-up. The measure of the glomerular
      filtration rate (GRF) in patients with chronic critical illness and controls (sepsis patients
      discharged from ICU before day 14) will be used to determine to what degree of kidney
      dysfunction contributes to decreased survival and increase in chronic kidney disease at year
      one after sepsis onset.

      One and/or all of the three ways for GFR assessment will be used, both at approximately day
      14 or approximately at the day of discharge from the ICU and at the one year follow up :

        1. Determine clearance of Iohexol from blood after Iohexol injection and/or

        2. Determine apperance of Iohexol in urine after Iohexol injection (this would be the same
           injection as in one, and would not require two injections) and/or

        3. A timed urine collection to determine clearance of urea and creatinine and/or

        4. Estimated GFR using calculations with serum creatinine and cystatin C,

      This will provide an opportunity to validate the different measurements.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve versus time curve (AUC) of Iohexol</measure>
    <time_frame>0, 1, 2, 3, and 4 hours post-dose</time_frame>
    <description>The decline in iohexol glomerular filtration rate at day 14 and 1 year follow-up between chronic crucial illness and control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>Day 14</time_frame>
    <description>The correlation between iohexol glomerular filtration rate and estimated glomerular filtration rate using previously validated equation applied to serum creatinine in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>1 year</time_frame>
    <description>The correlation between iohexol glomerular filtration rate and estimated glomerular filtration rate using previously validated equation applied to serum creatinine in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Urea Concentration</measure>
    <time_frame>Day 14</time_frame>
    <description>The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of urea concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Urea Concentration</measure>
    <time_frame>1 year</time_frame>
    <description>The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of urea concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Creatinine Ratio</measure>
    <time_frame>Day 14</time_frame>
    <description>The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Creatinine Ratio</measure>
    <time_frame>1 year</time_frame>
    <description>The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Inhospital group at day 14</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of sepsis participants will remain hospitalized after day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Released from hosptial prior to day 14</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group of sepsis participants will be released from the hospital prior to day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.</description>
    <arm_group_label>Inhospital group at day 14</arm_group_label>
    <arm_group_label>Released from hosptial prior to day 14</arm_group_label>
    <other_name>omnipaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine Collection</intervention_name>
    <description>Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.</description>
    <arm_group_label>Inhospital group at day 14</arm_group_label>
    <arm_group_label>Released from hosptial prior to day 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.</description>
    <arm_group_label>Inhospital group at day 14</arm_group_label>
    <arm_group_label>Released from hosptial prior to day 14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence in the surgery or trauma ICU

          -  Age of â‰¥18 years

          -  Entrance into our sepsis protocol

          -  Ability to obtain informed consent.

        Exclusion Criteria:

          -  Expected lifespan of the patient is less than 3 months due to severe pre-existing
             comorbidities (ex. recurrent, advanced or metastatic cancer)

          -  Severe traumatic brain injury (evidence of neurologic injury on CT scan and a GCS &lt;8)

          -  Refractory shock (i.e., patients who die within 12 hours)

          -  Uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable
             dead bowel)

          -  Patient or patient's family are not committed to aggressive management of the
             patient's condition and/or the patient has a DNR/DNI on file.

          -  Severe CHF (NY Heart Association Class IV)

          -  Child-Pugh C liver disease or pre-liver transplant.

          -  Known HIV infection with CD4 count &lt;200 cells/mm3

          -  Organ transplant recipient on immunosuppressive agents

          -  Known pregnancy and mother's that are breastfeeding

          -  Prisoners

          -  Institutionalized patients

          -  Inability to obtain informed consent.

          -  Chemotherapy or radiotherapy within 30 days prior to sepsis.

          -  End stage renal disease on admission.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Segal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Lanz, MSN</last_name>
    <phone>352-273-5497</phone>
    <email>jennifer.lanz@surgery.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Azra Bihorac, M.D.</last_name>
    <phone>352-273-9009</phone>
    <email>ABihorac@anest.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UF Health at Shands hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lanz, MSN</last_name>
      <phone>352-273-5497</phone>
      <email>jennifer.lanz@surgery.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Davis, ASN</last_name>
      <phone>325-273-5497</phone>
      <email>ruth.davis@surgery.ufl.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney dysfunction</keyword>
  <keyword>chronic critical illness</keyword>
  <keyword>sepsis</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

